Why would ACT issue a press release in variance from the actual paper published in Nature? To garner a mountain free, positive publicity, to be sure. But to what end? Follow the money. Here is a potential answer. In the wake of this mass media stampede, ACT’s stock has risen about 400%. Investors should do their due diligence more carefully. ACT has a history of money problems temporarily remedied by hyped stories about their supposed breakthroughs that later turn out to have been less than meets the eye.
Comments are visible to subscribers only. Log in or subscribe to join the conversation.
